No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response

Neuroscience Letters

Volumn 280, Issue 1, 2000, Pages 65-68

  Bolonna, A A ^a   Arranz, M J ^a   Munro, J ^a   Osborne, S ^a   Petouni, M ^a   Martinez, M ^a   Kerwin, R W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adrenergic receptors; Clozapine response; Pharmacogenetics; Schizophrenia

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; CLOZAPINE;

ADRENERGIC SYSTEM; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN POLYMORPHISM; SCHIZOPHRENIA;

AMINO ACID SUBSTITUTION; ANTIPSYCHOTIC AGENTS; CLOZAPINE; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; REFERENCE VALUES; SCHIZOPHRENIA;

EID: 0033956560     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(99)01000-9     Document Type: Article

References (20)

1. Arnsten A.F.T., Mathew R., Ubriani R., Taylor J.R., Li B.M. alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol. Psychiatry. 45:1999;26-31.
2. Arranz M.J., Munro J., Sham P., Kirov G., Murray R.M., Collier D.A., Kerwin R.W. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizopr. Res. 32:1998;93-99.
3. Baldessarini R.J., Hustonlyons D., Campbell A., Marsh E., Cohen B.M. Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br. J. Psychiat. 160:1992;12-16.
4. Bono M., Cases A., Oriola J., Calls J., Torras A., Rivera F. Polymorphisms of the human α2A-adrenergic receptor gene in a Catalan population: description of a new polymorphism in the promoter region. Gene Geogr. 10:1996;151-160.
5. De Paermentier F., Mauger J.M., Lowther S., Crompton M.R., Katona C.L.E., Horton R.W. Brain alpha-adrenoceptors in depressed suicides. Brain Res. 757:1997;60-68.
6. Feng J., Sobell J.L., Heston L.L., Goldman D., Cook E., Kranzler H.R., Gelernter J., Somer S.S. Variants in the alpha (2A) adrenergic receptor gene in psychiatric patients. Am. J. Med. Genet. (Neuropsychiatric Genetics). 81:1998;405-410.
7. Garcia-Sevilla J.A., Escriba P.V., Ozaita A., La Harpe R., Walzer C., Eytan A., Guimon J. Up-regulation of immunolabeled alpha (2A)-adrenoceptors G(i) coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J. Neurochem. 72:1999;282-291.
8. Gurguis G.N.M., Antai Otong D., Vo S.P., Blakeley J.E., Orsulak P.J., Pety F., Rush A.J. Adrenergic receptor function in panic disorder - I. Platelet alpha(2) receptors: G(i) protein coupling, effects of imipramine, and relationship to treatment outcome. Neuropsychopharmacology. 20:1999;162-176.
9. Halperin J.M., Newcorn J.H., Kida V.H., Pick L., McKay K.E., Knott P. Noradrenergic mechanisms in ADHD children with and without reading disabilities: a replication and extension. J. Am. Acad. Child Psych. 36:1997;1688-1697.
10. Ipsen M., Zhang Y.Y., Dragsted N., Han C.D., Mulvany M.J., Lundbeck H. The antipsychotic drug sertindole is a specific inhibitor of alpha (1A)-adrenoceptors in rat mesenteric small arteries. Eur. J. Pharmacol. 336:1997;29-35.
11. Lario S., Calls J., Cases A., Oriola J., Torras A., Rivera F. Msp I identifies a biallelic apolymorphisms in the promoter region of the α2A-adrenergic receptor gene. Clin. Genet. 51:1997;129-130.
12. Litman R.E., Su T.-P., Potter W.Z., Hong W.W., Pickar D. Idazoxan and response to typical neuroletpics in treatment-resistant schizophrenia. Br. J. Psychiatry. 168:1996;571-579.
13. Maes M., Van Gastel A., Delmeire L., Meltzer H.Y. Decreased platelet alpha-2 adrenoceptor density in major depression: effects of tricyclic. Biol. Psychiatry. 45:1999;278-284.
14. Meltzer H.Y. Role of serotonin in the action of atypical antipsychotic drugs. Clin. Neurosci. 3:1995;64-75.
15. Mori H., Koyama T., Yamashita I. Platelet alpha-2 adrenergic receptor-mediated phosphoinositide response in endogenous-depression. Life Sci. 48:1991;741-748.
16. Nutt D.J., Lalies M.D., Lione L.A., Hudson A.L. Noradrenergic mechanisms in the prefrontal cortex. J. Psychopharmacol. 11:1997;163-168.
17. Ordway G.A., Widdowson P.S., Smith K.S., Halaris A. Agonist binding to alpha (2)-adrenoceptors is elevated in the locus-coeruleus from victims of suicide. J. Neurochem. 63:1994;617-624.
18. Shibata K., Hirasawa A., Moriyama N., Kawabe K., Oawa S., Tsujimoto G. Alpha (1a)-adrenoceptor polymorphims: Pharmacological characterization and association with benign prostatic hypertrophy. Br. J. Pharmacol. 118:1997;1403-1408.
19. Sodhi M.S., Arranz M.J., Curtis D., Ball D., Sham P., Robert G.W., Price J., Collier D., Kerwin R. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. NeuroReport. 7:1995;169-172.
20. Sodhi M.S., Murray R.M. Future therapies for schizophrenia. Exp. Opin. Ther. Patents. 7:1997;151-165.